Freenome rais­es $254M for ear­ly can­cer de­tec­tion tests

Freenome has raised an ad­di­tion­al $254 mil­lion in pri­vate fund­ing, led by Roche, as the com­pa­ny nears piv­otal re­sults for its blood-based can­cer test.

San Fran­cis­co-based Freenome is among the liq­uid biop­sy com­pa­nies that seek to pick up on can­cer be­fore pa­tients show symp­toms. While com­peti­tor Grail aims to de­tect dozens of can­cers, Freenome has tak­en a nar­row­er ap­proach, with an ear­ly fo­cus on col­orec­tal can­cer, the sec­ond-lead­ing cause of can­cer deaths.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER